Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer; * 18-75 years old (including 18 and 75 years old); * No BRCA1/2 or PALB2 mutation; * No previous pancreatic cancer resection, systemic therapy, or local radiation therapy; * Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; * Life expectancy ≥ 6 months; * At least one measurable lesion according to RECIST version 1.1; * Adequate organ and bone marrow functions; * Women of childbearing age need to take effective contraceptive measures. Exclusion Criteria: * With distant metastasis; * Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment; * Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.); * Allergic to the study drug or any of its adjuvants; * Researchers judged clinically significant electrolyte abnormalities; * History of serious cardiovascular and cerebrovascular diseases; * With active ulcer, intestinal perforation and intestinal obstruction; * Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator); * Clinically significant electrolyte abnormalities judged by researchers; * With active bleeding or o…